Due to its restricted specificity for differentiated cells of the B-cell lineage, CD37 was considered to be a potential target for the treatment for B-cell lymphoma using an anti-CD37 antibody radiolabeled with iodine-131 (β−; T1/2 = 8.02 d; 606 keV). The gene discussed is CD37; the disease is B-cell non-Hodgkin lymphoma.